Comment: Immunogenicity of biosimilars

Comment: Critical quality attributes of biosimilars

Comment: Use of biosimilar monoclonal antibodies in the clinic

Comment: Supporting a sustainable biosimilar solution

Realising the potential of biosimilars

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

Checkmate 227: Final analysis for the non small cell lung cancer trial

PARP inhibitors for metastatic breast cancer